Small Cell Lung Cancer Patients Can Benefit from Immunotherapy

GRACE Videos and Articles

ASCO 2015 Highlights 05

 

The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).

[powerpress]

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation